{
 "edition": "20260908-21",
 "language": "en",
 "period_start": "2026-09-08T21:00:00+09:00",
 "period_end": "2026-09-09T00:00:00+09:00",
 "page": 2,
 "pages": 2,
 "received_in_period": 104,
 "listed_in_period": 104,
 "description": "One place for news and notices from 2 countries/regions: Taiwan, 87 items from 4 sources; Japan, 17 items from 1 source.One edition every 180 minutes: every item from every source received in the period, with the original link.",
 "countries": [
  {
   "code": "TW",
   "name": "Taiwan",
   "items": 87,
   "sources": 4
  },
  {
   "code": "JP",
   "name": "Japan",
   "items": 17,
   "sources": 1
  }
 ],
 "number_of_items": 4,
 "items": [
  {
   "id": 2589255,
   "anchor": "n2589255",
   "permalink": "https://ainews.idaeo.ai/180m/20260908-21/index-en-p2.html#n2589255",
   "title": "華安 (6657) shareholders to participate in 源華智醫’s year 115 cash capital increase; payment call period runs from 9/11 to 10/12 — Global Bio & Investment Monthly",
   "title_state": "translated",
   "summary": "",
   "summary_state": "none",
   "facts": [],
   "companies": [
    "華安",
    "源華智醫"
   ],
   "published_at": "2026-09-08T01:00:00+09:00",
   "source_type": "gbimonthly",
   "source_name": "環球生技月刊",
   "country": "TW",
   "country_name": "Taiwan",
   "source_language": "zh-TW",
   "summary_language": "zh-TW",
   "url": "https://news.gbimonthly.com/tw/invest/show.php?num=90041&range=news",
   "link_level": "source",
   "link_label": "Original",
   "site_url": null,
   "merged_count": 1,
   "merged_ids": [],
   "merged_urls": []
  },
  {
   "id": 2589254,
   "anchor": "n2589254",
   "permalink": "https://ainews.idaeo.ai/180m/20260908-21/index-en-p2.html#n2589254",
   "title": "One-year study results for 鼎晉’s long-acting botulinum toxin type A show an adverse event rate of 0.7% — Global Bio & Investment Monthly",
   "title_state": "translated",
   "summary": "",
   "summary_state": "none",
   "facts": [
    {
     "text": "The adverse event rate was 0.7%",
     "state": "translated",
     "quote": "不良事件發生率為0.7%"
    },
    {
     "text": "The study enrolled 200 participants",
     "state": "translated",
     "quote": "該研究共納入200名受試者"
    },
    {
     "text": "A total of 432 treatment sessions have been completed",
     "state": "translated",
     "quote": "累計完成432人次治療"
    },
    {
     "text": "OBI-858, a 760kDa long-acting botulinum toxin type A drug",
     "state": "translated",
     "quote": "760kDa長效型A型肉毒桿菌素新藥OBI-858"
    }
   ],
   "companies": [
    "鼎晉生技"
   ],
   "published_at": "2026-09-08T01:00:00+09:00",
   "source_type": "gbimonthly",
   "source_name": "環球生技月刊",
   "country": "TW",
   "country_name": "Taiwan",
   "source_language": "zh-TW",
   "summary_language": "zh-TW",
   "url": "https://news.gbimonthly.com/tw/invest/show.php?num=90024",
   "link_level": "source",
   "link_label": "Original",
   "site_url": null,
   "merged_count": 1,
   "merged_ids": [],
   "merged_urls": []
  },
  {
   "id": 2589253,
   "anchor": "n2589253",
   "permalink": "https://ainews.idaeo.ai/180m/20260908-21/index-en-p2.html#n2589253",
   "title": "The 15th class of ITRI fellows announced; Taipei Veterans General Hospital President Chen Wei-ming selected in recognition of his contributions to medicine — Global Bio & Investment Monthly",
   "title_state": "translated",
   "summary": "",
   "summary_state": "none",
   "facts": [
    {
     "text": "3 newly appointed fellows",
     "state": "translated",
     "quote": "3位新任院士"
    }
   ],
   "companies": [
    "工業技術研究院",
    "台積電",
    "瑞昱半導體",
    "臺北榮民總醫院"
   ],
   "published_at": "2026-09-07T01:00:00+09:00",
   "source_type": "gbimonthly",
   "source_name": "環球生技月刊",
   "country": "TW",
   "country_name": "Taiwan",
   "source_language": "zh-TW",
   "summary_language": "zh-TW",
   "url": "https://news.gbimonthly.com/tw/invest/show.php?num=90009",
   "link_level": "source",
   "link_label": "Original",
   "site_url": null,
   "merged_count": 1,
   "merged_ids": [],
   "merged_urls": []
  },
  {
   "id": 2589252,
   "anchor": "n2589252",
   "permalink": "https://ainews.idaeo.ai/180m/20260908-21/index-en-p2.html#n2589252",
   "title": "保瑞’s August revenue hit a historic second-high of NT$2.18 billion, up 59% year on year - Global Bio & Investment",
   "title_state": "translated",
   "summary": "",
   "summary_state": "none",
   "facts": [
    {
     "text": "Self-reported consolidated revenue for August was NT$2.18 billion",
     "state": "translated",
     "quote": "8月自結合併營收為新台幣21.8億元"
    },
    {
     "text": "Year-on-year growth of 59.22%",
     "state": "translated",
     "quote": "年增59.22%"
    },
    {
     "text": "Revenue for the first 8 months of this year totaled NT$13.979 billion",
     "state": "translated",
     "quote": "累計今年前8月營收達139.79億元"
    },
    {
     "text": "Up 6.09% year over year",
     "state": "translated",
     "quote": "年增6.09%"
    }
   ],
   "companies": [
    "保瑞藥業",
    "保瑞"
   ],
   "published_at": "2026-09-07T01:00:00+09:00",
   "source_type": "gbimonthly",
   "source_name": "環球生技月刊",
   "country": "TW",
   "country_name": "Taiwan",
   "source_language": "zh-TW",
   "summary_language": "zh-TW",
   "url": "https://news.gbimonthly.com/tw/invest/show.php?num=90008",
   "link_level": "source",
   "link_label": "Original",
   "site_url": null,
   "merged_count": 1,
   "merged_ids": [],
   "merged_urls": []
  }
 ]
}